Major Depressive Disorder Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Emerging Trends

Which drivers are expected to have the greatest impact on the over the major depressive disorder market's growth?
The increase in substance and alcohol misuse incidents is projected to stimulate developments in the major depressive disorder market. Substance and alcohol misuse refers to the destructive and overutilisation of such substances, resulting in detrimental effects on physical health, mental well-being, and societal relations. They commonly accompany major depressive disorder, mutually intensifying each other, thereby elevating the likelihood of physical and psychological damage. As per a survey released in July 2024 by the Substance Abuse and Mental Health Services Administration, a US-based health and human services department, 3.1% of individuals (equalling 8.9 million) misused opioids in 2023, while 21.8% of people aged 12 or older were found using marijuana, the most frequently abused illicit drug. Also, 9.4% of individuals aged 12 and above were seen vaping nicotine in the previous month, marking an increase from 8.3% in 2022. Consequently, the surge in substance and alcohol misuse episodes is enhancing the major depressive disorder market dynamics. Feat driving the Major Depressive Disorder Market: Escalation in Anxiety Cases Spurs Market Evolution

Get Your Major Depressive Disorder Market Report Here:
https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

What is the future CAGR of the major depressive disorder market, and how will it impact industry expansion?
Over the past several years, there has been a consistent expansion in the market size for major depressive disorder. It is projected to increase from $6.12 billion in 2024 to about $6.28 billion in 2025, boasting a compound annual growth rate (CAGR) of 2.6%. The progress observed in the historical span is largely due to advancements in pharmaceuticals, greater public understanding of mental health, the use of psychological therapies, and initiatives in public health.

The market size for major depressive disorder is anticipated to witness consistent expansion in the upcoming years, reaching a value of $7.13 billion in 2029, with a compound annual growth rate (CAGR) of 3.2%. The increase during the projected period is attributed to factors like precision medicine, telepsychiatry and teletherapy, innovative treatment methods, and the worldwide expansion of mental health services. Notable trends predicted to emerge in this period include early intervention, support from peers, online communities, comprehensive strategies, and resilience and coping tools.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

What are the most significant trends transforming the major depressive disorder market today?
Prominent firms in the major depressive disorder market are concentrating on inventing revolutionary products and obtaining approval for them to maintain a competitive edge. The number of drug approvals for the treatment of major depressive disorder is rising due to the increasing demand for safer and more effective therapies. For example, in December 2022, American pharmaceutical company, AbbVie Inc., received the green light from the US-based federal agency, Food and Drug Administration (FDA), for VRAYLAR (cariprazine) to be used as a support therapy alongside antidepressants for adults suffering from major depressive disorder (MDD). VRAYLAR is a groundbreaking atypical antipsychotic medication that manages dopamine and serotonin concentrations in the brain. It stands as the first of its kind to be approved as a complementary treatment for major depressive disorder. It comes in tablet form and is to be taken once daily.

Which key market segments comprise the major depressive disorder market and drive its revenue growth?
The major depressive disorder market covered in this report is segmented -

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments
2) By Diagnosis: Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5), Other Diagnosis
3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:
1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy
2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants
3) Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT
4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)
5) Other: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13042

What regions are at the forefront of major depressive disorder market expansion?
North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the leading players fueling growth in the major depressive disorder market?
Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13042&type=smp

What Is Covered In The Major Depressive Disorder Global Market Report?

•Market Size Forecast: Examine the major depressive disorder market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the major depressive disorder market for a structured understanding.
•Key Players Overview: Analyze major players in the major depressive disorder market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the major depressive disorder market.
•Segment Contributions: Evaluate how different segments drive overall growth in the major depressive disorder market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the major depressive disorder market.
•Industry Challenges: Identify potential risks and obstacles affecting the major depressive disorder market.
•Competitive Landscape: Review strategic developments in the major depressive disorder market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.